Sales Operations Associate jobs in Newton, MA

The Role

At Curie, we do early diligence differently. While most venture funds have their most junior team members as the filter for new inbound companies, Curie does the opposite. We believe that spotting the next great therapeutics company is hard, especially at the idea stage. It not only requires deep industry experience but also the imagination and creativity to elevate the initial idea from good to great. “Elevation” may entail everything from changing the proposed targets of an exciting new drug embodiment technology to finding the right drug embodiment approach of a fundamentally new biological insight. This is why Curie approaches early diligence with a ‘lead-from-the-front’ mentality, putting our most senior drug hunters at the top of the funnel to reduce the chance of a false negative mistake that could cause us to miss the next great therapeutics company. 

We are looking to hire an Associate to join our Company Evaluation & Diligence Team to ensure we are able to pick the right companies to invest in…at scale. At Curie, we see thousands of exciting new therapeutic concepts every year across all therapeutic areas and modalities. To handle this level of scale without sacrificing quality, we’ve had to develop a suite of internal tools and design processes to ensure we have the right people, reviewing the right companies, in a highly efficient, timely manner. Day to Day, you operate at the top of the funnel of Curie’s investment process. In this role, you will have the opportunity to see all companies that come our way (a few thousand new ideas per year), providing a rare and truly unique ‘birdseye view’ of the drug discovery landscape. You will be one of the primary people responsible for ensuring that our Intake process is highly efficient, accurate, and overall a great experience for the Founders we interact with. 

Our ideal candidate is someone with a deep passion for therapeutics, a get-stuff-done mentality, and a type A personality that does not let the important details fall through the cracks. In this role, you will need to be process-oriented and hold a high bar for the quality of your work. In addition to interacting with our Company Evaluation & Diligence Team, you will work closely with our Expert Network and Infrastructure team to help ensure we are always improving the quality and efficiency of the diligence process. 

The Responsibilities

• Extract the relevant information from inbound company materials (presentations, documents, etc) and synthesize the most important pieces into Curie’s internal tools/database
• Work in collaboration with our senior scientific team to gather additional information from founders to help drive our diligence process toward a go/no-go decision
• Ensure Curie is both responsive and clear in our communications with founders during the Intake process 
• Use and improve Curie’s internal tools to consistently drive improvements in the quality and efficiency of our Intake process 
• Ensure that there are no dropped balls along the way

Our Ideal Candidate

• At least 3 years of work experience in biotech or pharma
• High attention to detail
• Excellent written communication skills
• Bonus Points: a PhD in biology, biochemistry, or related discipline with experience 

Company Overview

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.

Curie.Bio was designed by founders for founders. Our founding team of Zach Weinberg, Christoph Lengauer and Alexis Borisy, has collectively helped start numerous therapeutics companies and been intimately involved with the Series A financing of many more. We have witnessed first hand the difficulty of going from a seed stage concept to generating the data package necessary for a successful Series A raise; targets need to be properly selected, experiment plans designed, vendors selected and contracted, experiments need to be run, people need to be hired - all with a few million dollars. These perennial challenges are what led to the creation of Curie.Bio. If we want to dramatically increase the number of viable drug companies created every year - we’re going to have to reduce the complexity of getting to a compelling POC data package required for a Series A. Reducing this complexity requires us to provide real support to these new companies - support that is both strategic (think target selection, unique access to strategic partnerships, early introductions to top Series A investors) and operational (experiment execution, vendor management, back office support).